Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech has recruited first patient in a Dose Escalating Phase of its Phase Ib/IIa clinical trial, Safety and Tolerability of An RNAi Therapeutic in FAP or START-FAP, with CEQ508 which is intended to treat Familial Adenomatous Polyposis (FAP).
Subscribe to our email newsletter
Upon recruitment, patients will be placed in one of four dose-escalating cohorts.
Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose.
CEQ508 will be administered daily in an oral suspension for 28 consecutive days.
Marina Biotech president and CEO Michael French said they are pleased to announce patient enrollment — a first step, in what they hope will be a rapid regulatory and clinical timeline to the commercialization of CEQ508 for the treatment of patients with FAP.
"Patients participating in the START-FAP trial will make a significant commitment throughout the trial period as each patient will undergo extensive pre- and post-dosing regimen procedures as well as daily visits by a home nurse to administer the CEQ508 dose," French said.